Anavex Life Sciences (NASDAQ:AVXL) Shares Up 5.2% - What's Next?

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) shot up 5.2% on Monday . The stock traded as high as $9.13 and last traded at $9.13. 340,574 shares were traded during mid-day trading, a decline of 73% from the average session volume of 1,264,724 shares. The stock had previously closed at $8.67.

Analyst Upgrades and Downgrades

A number of analysts have commented on AVXL shares. D. Boral Capital restated a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, February 12th. HC Wainwright reaffirmed a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, February 18th.

Anavex Life Sciences Trading Up 3.2 %

The firm has a market capitalization of $790.24 million, a P/E ratio of -16.90 and a beta of 0.94. The business's fifty day moving average is $9.48 and its 200 day moving average is $7.99.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.03. As a group, sell-side analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Anavex Life Sciences

A number of large investors have recently bought and sold shares of AVXL. Geode Capital Management LLC grew its position in Anavex Life Sciences by 2.8% during the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company's stock worth $10,699,000 after buying an additional 51,946 shares in the last quarter. Nwam LLC raised its stake in shares of Anavex Life Sciences by 0.3% in the fourth quarter. Nwam LLC now owns 913,051 shares of the biotechnology company's stock valued at $9,806,000 after purchasing an additional 2,575 shares in the last quarter. Northern Trust Corp lifted its position in Anavex Life Sciences by 1.6% in the fourth quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company's stock worth $7,592,000 after purchasing an additional 10,938 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Anavex Life Sciences by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company's stock worth $7,273,000 after buying an additional 11,239 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Anavex Life Sciences by 2,419.8% in the 4th quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company's stock valued at $6,606,000 after buying an additional 590,639 shares during the period. 31.55% of the stock is currently owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.